Sight Sciences cuts FY2023 guidance to $80-82M, cites LCD uncertainty; appoints Matt Link CCO

Sight Sciences, Inc.

Q3 guidance $19-20M; FY guidance cut to $80-82M from $89-94M (12-15% YoY growth).
Proposed LCDs by 5 of 7 MACs could classify non-implantable MIGS as investigational, affecting orders.
Matt Link appointed CCO; former NuVasive President who scaled revenue from <$100M to >$1B.
Link receives $410K base salary, 50% bonus target, $660K options, and $1.54M RSUs.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Matthew Link

Chief Commercial Officer

SGHT · Sight Sciences, Inc.

Effective: 2023-09-11
Filed: September 11, 2023, 7:59 PM ET

Effective September 11, 2023, Matthew Link was appointed by the board of directors (the “Board”) of Sight Sciences, Inc. (the “Company”) to serve as the Company’s Chief Commercial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew Link was appointed as Chief Commercial Officer at Sight Sciences, Inc..

Action: appointed
Role: Chief Commercial Officer

Exact text from the filing

Effective September 11, 2023, Matthew Link was appointed by the board of directors (the “Board”) of Sight Sciences, Inc. (the “Company”) to serve as the Company’s Chief Commercial Officer.

View on SEC.gov

Sight Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-232585

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.